GE Healthcare

Greenphire partners with Merge Healthcare

Thursday, January 19, 2012 01:05 PM

Greenphire has formed an exclusive strategic partnership with the clinical trials division of Merge Healthcare to offer integrated functionality between Merge’s EDC technology and Greenphire’s eClinicalGPS site and vendor payment management technology.

More... »

Clarient, ACORN collaborate to improve cancer treatment

Wednesday, December 14, 2011 12:22 PM

Clarient, a GE Healthcare company, and ACORN Research have formed a strategic collaboration around molecular testing of tumor samples. The agreement will establish a standardized testing protocol across the ACORN network of oncology community practices and hospitals with treatment guidelines and clinical trial opportunities. These processes have the potential to improve oncology treatment and research that aim to deliver targeted treatments based on the specific genetic markers for each patient.

More... »

Merge Healthcare names senior executives

Thursday, November 10, 2011 09:52 AM

More... »

Repligen acquires Novozymes business for $23 million

Friday, October 28, 2011 02:06 PM

Repligen has acquired the business of Novozymes Biopharma Sweden in a cash $22.7 million and future potential milestone payments of $5.6 million. This acquisition will elevate Repligen to a world-leading supplier of products for manufacturing biologic drugs with the potential to yield sustainable growth and profitability in fiscal year 2013, beginning April 1, 2012. The combined company is expected to generate total revenues of approximately $50 million in fiscal year 2013.

More... »

Clarient, HistroRxR to provide AQUA technology for clinical trials

Tuesday, October 25, 2011 02:38 PM

Clarient, a GE Healthcare company, and HistoRxR have signed a definitive agreement to provide pharma services using AQUA technology to their growing lists of pharma clients.  By implementing HistoRx's AQUA technology in Clarient's CLIA laboratory, the two companies will apply their complementary capabilities to serve pharma companies' growing need for biomarker analysis in clinical trials.  Use of tissue biomarkers to characterize a patient's tumor is becoming a crucial element of personalized cancer care.

More... »

Oracle to Acquire Phase Forward for $685M

Friday, April 16, 2010 02:37 PM

Business software giant Oracle, already a player in the eClinical space, plans to acquire market leader Phase Forward in a deal valued at approximately $685 million—or $17 per share in cash.

More... »

Encorium Acquisition Leads to CEO Move, COO Departure

Friday, July 24, 2009 11:39 AM

Wayne, Pa.-based contract research organization (CRO) Encorium Group has completed the sale of its U.S. business to Pierrel Research USA, a subsidiary of Italian CRO Pierrel SpA, for $2.7 million.

More... »

Etrials Pays $500K to Terminate Agreement with BioClinica

Wednesday, June 3, 2009 07:00 AM

Only days after BioClinica increased its purchase offer to acquire etrials Worldwide and the two companies agreed to proceed with their acquisition agreement, that agreement has been terminated.

More... »